Introduction
Posterior capsule opacification (PCO) is the most common postoperative complication after extracapsular cataract extraction (ECCE) or phacoemulsification [1] . The main cause of PCO is the transdifferentiation, proliferation, migration and collagen production of residual lens epithelial cells (LECs) in the capsule.
Studies have shown that multiple regulatory factors are involved in the occurrence and development of PCO [2] , including connective tissue growth factor (CTGF). CTGF is a crucial factor that was discovered in recent years and plays major roles in mitosis, fibroblastic proliferation, collagen synthesis, and cell adhesion, migration, and fibrosis [3] [4] [5] [6] [7] . CTGF promotes the fibrosis of LECs, trabecular meshwork cells and retinal pigment epitheliums. Therefore, CTGF is a major cause of many intraocular pathological changes [8] [9] [10] , and it is closely associated with transforming growth factor-β (TGF-β). Our previous studies found that CTGF is a downstream effector of TGF-β2 and participates in EMT and ECM synthesis and pathological changes in various cells, such as vascular smooth muscle cells (VSMCs) and LECs [11] [12] [13] [14] [15] . Studies have also found that CTGF induces the synthesis of the EMT-specific marker α-SMA and various ECM proteins, such as COL-1 and Fn by the LECs [16] .
Studies have shown that CTGF can activate multiple signalling pathways, including ERK, p38, JNK, ROS, ASK1 and NF-κB, and promote the Ivyspring International Publisher migration and proliferation of human Tenon's capsule fibroblasts, hepatic stellate cells (HSCs), hepatoma carcinoma cells, cardiomyocytes and glioma cells [17] [18] [19] [20] [21] [22] . Our former research findings showed that CTGF is under the regulation of the TGF-β/Smad signalling pathway. However, signalling pathways downstream of CTGF that are involved in the migration of HLECs and regulation of the production of EMT and ECM remain uncharacterized in HLECs.
After cataract surgery, the blood-aqueous barrier is damaged, which increases the expression of a cohort of growth factors and cytokines (CKs), including TGF-β, FGF and PDGF in the aqueous humour, which can stimulate EMT [23] . TGF-β has been shown to induce EMT in rat LECs; therefore, it plays an important role in rat anterior subcapsular cataracts (ASCs) and PCO [24] . AKT inhibitors have been found to effectively prevent canine PCO [25] . However, previous studied have not determined whether the specific inhibition of CTGF expression could effectively inhibit PCO.
In this study, we first tested the effects of CTGF on the capsule bag model, the activation of ERK, p38 and FAK signalling pathways and the migration ability of HLECs. Rat PCO models were then established to examine the impact of CTGF depletion on PCO development in vivo.
Materials and Methods

Culture and treatment of HLECs
The HLECs line SRA01/04 was gifted from the Ophthalmology Institute of the Fourth Military Medical University. A total of 1×10 6 cells within 20 passages were seeded into a culture flask with DMEM containing 10% foetal bovine serum (FBS). The culture medium was replaced with serum-free DMEM when the cells approached 70% confluence, and the cells were cultured for 24 h. The cells in the experimental group were then treated with 3 mL of serum-free medium containing CTGF at 60 μg/l for different durations (0, 5, 15, 30, 60, 120, 240, 480, 960 min and 24 h) before the cells were harvested for further analysis. Control group cells were treated with an equal volume of medium because all reagents were water soluble.
Making the Capsular Bag Model
Ten eyes of 5 pigs were obtained from an abattoir. Cornea was cut along the limbus. After the cornea was removed, capsular bags were prepared by hydrodissection followed by continuous curvilinear capsulorhexis. Then, separated lens from iris and suspensory ligament. The original shape of the capsular was maintained by IOL (OcuLens, RAFI Systems Inc., California, USA) into the capsular bag.
After treatment with CTGF at 60 μg/l or no treatment, the capsular bags were incubated in MEM (CM10010, M&C GENE TECHNOLOGY LTD., Beijing, China) medium for 14 days in an atmosphere of 5% CO2 at 37°C. The medium was changed every 48 hours. LECs proliferation was observed with an inverted microscope (Eclipse Ti, Nikon, Japan). The model was established, and the observation replicated three times in each treatment.
Transwell® migration assays
Transwell® migration experiments were performed with 24 well plates with Matrigel™-coated chambers (8μm pore size) from BD Biosciences. Cells were grown to 70% confluence and serum starved for 24 h. Following detachment with trypsin, cells were washed with PBS, resuspended in serum -free medium and 1x10 4 cells were added to the upper chamber. Serum-free medium containing 60 μg/l CTGF, 60 μg/l CTGF+20μM U0126 and with the corresponding amount of DMSO as control were added to the bottom wells of the chambers. After 24 and 48 h, the cells that had not migrated were removed from the upper face of the filters using cotton swabs, and the cells that had migrated were fixed and stained with crystal violet solution.
Wound Healing assay
The Culture-Insert 2 Well provides two cell culture reservoirs which has a special sticky and bio-compatible surface at the bottom side and are separated by a 500 μm thick wall. A cell suspension of HLECs at 3x10 5 cells/ml for 70 μl were seeded in the designated areas and then cultured at 37℃ in a humidified atmosphere containing 5% CO 2 . When cells were grown to 90% confluence, gently removed the Culture-Insert 2 Well by using sterile tweezers. The cells in the experimental group were then treated with serum-free medium containing 60 μg/l CTGF, 60 μg/l CTGF+20 μM U0126 and with the corresponding amount of DMSO as control for 48h. The cells migration were observed by an inverted microscope. The images of wound areas are analysed by Image J software.
Quantitative Real-time PCR and Western blot
The total RNA extraction, reverse transcription, the qPCR reaction and Western-blot were performed as our previous experiments. The PCR primers were designed and synthesized by TaKaRa Biotechnology (TAKARA BIO INC., Japan) as shown in table 1. The antibody were shown as follow: ɑ-SMA (ab5694, Abcam, UK), Fn (ab2413, Abcam, UK), COL-1 (AB745, Millipore, USA), p-ERK1/2 (#4370, CST, USA), ERK1/2 (#4695, CST, USA), p-p38 (#4511, CST, USA), p38 (#41666, CST, USA), p-JNK1/2(#4668, CST, USA), JNK1/2 (#9258, CST, USA), and β-actin (#4970, CST, USA), goat anti-rabbit IgG secondary antibody (#L3012, SAB, USA). 
PCO modelling
The animal care, handling and surgical procedures were in accordance with the relevant guidelines and regulations. All of the experimental protocols were approved by the Ethics Committee of Xi'an Jiao Tong University. A total of 70 healthy adult SD rats (provided by the Animal Experimentation Centre affiliated with the School of Medicine, Xi'an Jiaotong University) with an average weight of 200 g and a gender ratio of 1:1 were selected for the experiment. Pre-examinations were conducted on the rats under a slit lamp to ensure that the rats were free from eye diseases, such as corneal conditions or cataracts. The operation was performed on the left eye only. The target sequences for the rat CTGF.shRNA were as follows: GCAGTTGCAAATACCAGTGCA. A nonsilencing shRNA (sequence: siNC, TTCTCCGAACGTGTCACGT) was used as a control in all shRNA transfection experiments. The rats were divided randomly into 5 groups as follows: Group A (one intracameral injection of CTGF.shRNA AAV complex), Group B (two intracameral injections of the CTGF.shRNA AAV complex), Group C (three intracameral injections of the CTGF.shRNA AAV complex), Group D (one intracameral injection of nonsilencing shRNA (NC.shRNA) AAV), Group E (two intracameral injections of NC.shRNA), Group F (three intracameral injections of NC.shRNA) and Group G (balanced salt solution (BSS) control). The experiment was performed in a sequence of steps. First, an intraperitoneal injection of 700 μl 10% chloral hydrate was administered as anaesthesia. The disinfecting drape was placed, and oxybuprocaine (Santen Pharmaceutical Co., Ltd.) was applied to the conducting surface as anaesthesia. A 2.0-mm paracentesis knife (Alcon US) was used on the 11-point corneal surface. A viscoelastic agent (Tianjin Jingming New Technological Development Co., Ltd.) was used for the formation of the anterior chamber, and a discission needle was performed capsulectomy. Hydrodissection was performed, and the lens nucleus was delivered. A double-gun tube (66 VISION TECH Co., Ltd.) was employed to suction the residual cortex of the lens, 2 µl CTGF shRNA (Shanghai Neuron Biotech) was injected into the capsular bag, and 5 µl dexamethasone + 5 µl tobramycin + 5 µl atropine was injected peribulbarly. One needle was used to suture the corneal incision. After surgery, the animals were fed routinely and received eye drops containing levofloxacin (Santen Pharmaceutical Co., Ltd.) four times daily, and TobraDex (Alcon US) was administered twice daily. The formation of PCO was observed under the slit lamp microscope. The rats were sacrificed on the sixtieth day, and their eyeballs were retrieved.
Immunostaining
Immunostaining was performed as our previous study [26] . The primary antibodies as follow: α-SMA, ab7817(the capsular bag) and ab5694 (The paraffins sections), abcam, UK; CTGF, ab6992, abcam, UK). Secondary antibodies as follow: fluorescein conjugated IgG (Alexa Fluor goat anti-mouse IgG, 1:400, Invitrogen); Strept-Avidin Biotin Complex (sp-9000, ZSGB-BIO, China).
Statistical analysis
The GraphPad Prism 5.0 statistics software was employed to perform all of the statistical analyses. All of the data are reported as the mean ± SD from at least three independent in vitro experiments. Statistical comparisons of the Transwell, real-time PCR and Western blot data with the control group were analysed using a one-way ANOVA, whereas differences between groups were compared using Tukey's HSD test. Differences of p<0.05 were considered statistically significant.
Results
CTGF promote LECs proliferation and EMT specific protein in a Capsular Bag Model
We investigated the impact of CTGF on the EMT and proliferation ability of LECs using a capsular bag model. We cultured capsular bags with or without CTGF. After being incubated with CTGF ( Figure 1A ), the number of LECs were obvious increased compared with control ( Figure 1F ). Furthermore, we used immunofluorescence staining to test the expression of α-SMA in the capsular bag. There were few α-SMA proteins in the control. Nevertheless, the expression of α-SMA were significant increased after treatment with CTGF. The results indicated that CTGF could induce LECs EMT specific protein and promote LECs proliferation in capsular bag model. 
Activation of ERK, p38 and JNK signalling pathways by CTGF
In different tissues, CTGF exerts its biological effects by activating different signalling pathways [27, 28] . However, the signalling pathways that are activated downstream of CTGF during PCO development are not well understood. Therefore, we analysed the effect of CTGF on a variety of signalling pathways. The HLECs were treated with 60 μg/l CTGF for different durations (0, 5, 15, 30, 60, 120, 240, 480 and 960 min), and then the expression of the p-ERK1/2, ERK1/2, p-p38, p38, p-JNK1/2 and JNK1/2 proteins were detected by Western blot. The results indicated that the CTGF treatment increased the expression of p-ERK1/2 in a time-dependent manner, whereas the total ERK1/2 proteins were not changed (Figure 2 A, B) . However, the expression of p-p38, p-JNK1/2, p38 and JNK1/2 did not show apparent changes (Figure 2 C, D) . Thus, we concluded that CTGF activates the ERK signalling pathway in HLECs.
Role of ERK signalling pathway in EMT and ECM synthesis in HLECs treated with CTGF
Our previous studies showed that the CTGF treatment induced the expression of EMT markers and ECM protein synthesis in HLECs [11] . Because CTGF activates the ERK signalling pathway in HLECs, we wondered whether the ERK signalling pathway was involved in the CTGF-induced expression of EMT markers and ECM proteins in HLECs. The HLECs were treated with the MEK inhibitor 20 μM U0126 to block the ERK signalling pathway and then treated with CTGF for 24 h. Consistent with prior observations, the mRNA and protein expression of α-SMA, Fn and COL-1 increased significantly after treatment with 60 μg/l CTGF compared with that of the control group. Nonetheless, the induction of α-SMA, Fn and COL-1 by CTGF at both the mRNA and protein levels was significantly inhibited by blocking the ERK signalling pathway with U0126 ( Figure 3) . 
Effect of the CTGF and ERK signalling pathways on HLECs migration
HLECs migration is one of the most important contributors to PCO development. Studies have shown that CTGF can promote migration in a variety of cells [29, 30] . However, the effect of CTGF on the migration of HLECs is still unknown. We investigated the impact of CTGF on the migration ability of HLECs using Transwell® migration assay and Wound-Healing assay. The results showed the number of migrated cells and migration rate of CTGF group were significantly higher than the control group (**p<0.01, Figure 4 ). Co-treatment with CTGF and U0126 significantly reduced the number of migrated cells and migration rate compared with the CTGF treatment alone ( ## p<0.01, Figure 4) . Interestingly, the number of migrated cells and migration rate were still significantly higher in the CTGF+U0126 group versus the control group (*p<0.05, **p<0.01), suggesting other downstream effectors, in addition to ERK signalling may also be involved in the migration-promoting effect of CTGF.
Figure 4. CTGF promoted the migration of HLECs in an ERK signalling-dependent manner. A:
HLECs were induced with 60 μg/l CTGF in the presence or absence of 20 µM U0126 for 24h, and the effect on migration was evaluated using the Transwell assay. Scale bar: 50 µm. B: Quantitation of the Transwell assay, ** p<0.01; The migration rates were significant between CTGF and CTGF+U0126 groups at 24h and 48h ## p<0.01. C: HLECs were induced with 60 μg/l CTGF in the presence or absence of 20 µM U0126 for 24h and 48h, and the effect on migration was evaluated using the wound healing assay. Scale bar: 100 µm. D: The migration rates were significant in CTGF and CTGF+U0126 groups compared with control at 24h and 48h * p<0.05; The migration rates were significant between CTGF and CTGF+U0126 groups at 24h and 48h ## p<0.01.
Effects of specific CTGF silencing on rat PCO
TGF-β2 is considered an important factor in the development of PCO [16] , and it plays an important role in maintaining the physiological function of the body; moreover, blocking this factor will cause a series of pathological changes. Thus, a factor that is specific and essential for tissue fibrosis and does not promote severe pathological changes after its expression is blocked must be targeted. CTGF has been shown to act as a downstream effector of TGF-β2, which is mainly involved in the process of fibrosis in various tissues [12, 13] . Therefore, we hypothesized that targeting CTGF may delay the onset of PCO or alleviate its symptoms. To test this hypothesis, we injected CTGF.shRNA with an AAV vector to silence the expression of CTGF and observe the associated effects on PCO occurrence in a rat PCO model. The results showed that the BSS group, one intracameral injection, two intracameral injections and three intracameral injections of the NS groups developed PCO after 20 days and opacification became obvious on the 40th day. The capsules of the groups with one or two intracameral injections of CTGF shRNA were transparent on day 40, although partial opacification was observed on day 60. Remarkably, the capsules of the group with 3 intracameral injections of CTGF shRNA did not show obvious opacification on the 60th day ( Figure 5 ). 
Assessment of PCO
The PCO assessment was compared among the seven groups with EPCO software (http://www.epco2000.de/). The PCO grades were shown in table 2. The results showed that the BSS group, one intracameral injection, two intracameral injections and three intracameral injections of the NC.shRNA groups PCO scores were significant higher than three intracameral injections of the CTGF.shRNA AAV group (** p<0.01, Figure 6 ). The one intracameral injections of the CTGF.shRNA AAV group PCO score was significant higher than three intracameral injections of the CTGF.shRNA AAV group (* p<0.05, Figure 6 ). However, there was no significant difference between three intracameral injections of the CTGF.shRNA AAV group and two intracameral injections of the CTGF.shRNA AAV group ( Figure 6 ). Together, our results indicated that specific blockade of CTGF can effectively prevent or delay the occurrence of PCO.
Effects of specific CTGF silencing on the post-cataract expression of CTGF and α-SMA protein in the rat lens capsule CTGF is rarely expressed in normal tissues, although damage to the blood-aqueous barrier by external forces, such as surgery or trauma, increases the expression of CTGF [17, 31] . We conducted ECCE on SD rats, sacrificed the rats after 60 days and observed the expression of CTGF and α-SMA protein in the lens capsule using immunohistochemical staining. The results showed that the expression of CTGF and α-SMA protein increased significantly in the BSS control group and the two intracameral injections of the NC.shRNA group ( Figure 7B , C, F, G), whereas the expression decreased in the group that had 3 injections of CTGF.shRNA AAV ( Figure  7A , E). We did not observe any expression of CTGF and α-SMA protein in the non-surgery group ( Figure  7D, H) . These results indicated that the CTGF-specific shRNA successfully blocked the surgery-induced upregulation of CTGF and α-SMA in residual rat LECs.
Discussion
PCO is the most common complication after ECCE or phacoemulsification. The main cause of PCO is the transdifferentiation, proliferation, migration and collagen production of LECs in the capsule. Currently, YAG is the main treatment for PCO, although intraocular lens injury may occur during the operation, and complications such as macular oedema, elevated intraocular pressure and retinal detachment may occur after surgery. Therefore, developing new approaches to prevent the occurrence of PCO has become a popular research endeavour in recent years, and the role of growth factors and cytokines in fibrosis development has drawn increasing attention. CTGF is an important recently discovered secretory growth factor, and it occurs in a variety of human tissues and organs and exhibits especially high contents in the kidney. In different tissues, CTGF exerts its biological effects via binding with different receptors [32, 33] . In-depth studies on the relationship between CTGF and PCO and the functional mechanisms have provided rationales for focusing on CTGF as a potential target for PCO prevention and treatment. CTGF plays an important role in many eye diseases, such as glaucoma and vitreous retinal disease, and is vital for corneal repair [12, [34] [35] [36] [37] . Moreover, CTGF may act as a downstream effector of TGF-β to promote fibrosis and stimulate fibroblast proliferation and ECM synthesis, and it also promotes wound healing and tissue fibrosis [9, 38, 39] . The EMT of LECs is the main pathological change associated with PCO [14] , which is characterized by cell morphology changes, epithelial phenotype loss, actin reorganization and interstitial cell phenotypes. α-SMA is an important marker of EMT and a key factor in tissue fibrosis. The rearrangement of the actin cytoskeleton and the induction of α-SMA during EMT provide a structural basis for the migration, invasion and contractility of the transdifferentiated cells. As the main ECM components, COL-1 and Fn are distributed on the cell surface or between cells, where they form a network structure to provide support for the migration of cells. CTGF played different proliferation effects in different cells, but CTGF could definitely promote fibroblast proliferation [40] [41] [42] . In order to better investigate the effects of CTGF on LECs EMT and proliferation, we use a capsular bag model. Our results indicated that LECs happened EMT and proliferation after being induced by CTGF. Furthermore, because some LECs gathered into a mass and happened differentiation, it was difficult to statistics the number of LECs. However, it was also obvious that the number of cells and the expression of α-SMA were significant increased after treatment with CTGF.
The ERK, p38 and JNK signalling pathways are involved in EMT and ECM production of a variety of cells [43] [44] [45] [46] [47] . It has been found that CTGF could activate Ras/MEK/ERK/STAT3 pathway. Selective inhibitors of Ras, MEK 1/2, and ERK1/2 individually blocked both CTGF induced cell proliferation, and collagen gel contraction [48] . However, previous studies have not been performed to investigate the relationship of the ERK, p38 and JNK signalling pathways with CTGF-induced EMT specific protein and ECM synthesis in HLECs. Our previous results showed that CTGF can promote EMT and ECM production in HLECs in a Smad signalling-dependent manner [11] . The results of the current study indicated that the ERK pathway but not the p38 or JNK signalling pathways was activated by CTGF and contributed to CTGF-induced EMT specific protein and ECM synthesis in HLECs. This observation is consistent with a previous study in glioma cells [20] . Interestingly, CTGF was found to promote fibrosis in various tissues by activating the TGF-β/Smad signalling pathway, thus implying the presence of a positive feedback loop.
Studies have shown that CTGF promotes the migration and proliferation of HSCs and hepatoma carcinoma cells [5] . In glaucoma, CTGF promotes the migration of human Tenon's capsule fibroblasts, which could be blocked by paclitaxel [21] . However, the effect of CTGF on the migration of HLECs has not been studied. Our present study provides the first evidence that CTGF could enhance the migratory capacity of HLECs. Blocking the ERK signalling pathway effectively decreased the migration of HLECs induced by CTGF, although this migration was not completely inhibited. The pro-migratory effect of CTGF may represent an integrated outcome of the actions of multiple factors and signalling pathways; therefore, the inhibition of one of these factors or pathways cannot block the process completely. Further studies are needed to fully investigate this issue.
Studies have shown that blocking Akt signalling effectively prevented the occurrence of canine PCO, and medicines such as fluorouracil (5-FU), nonsteroidal anti-inflammatory drugs (NSAIDs), diclofenac, doxorubicin and celecoxib could also reduce the occurrence of PCO [49] [50] [51] . Our previous study showed that blocking the expression of CTGF effectively inhibited TGF-β2-induced EMT and ECM production in HLECs. However, whether specific inhibition of CTGF expression can effectively inhibit PCO is still unclear. Studies have found that inhibiting the expression of CTGF provided a meaningful reduction in renal fibrosis [52] . Research has shown that vaccination against CTGF inhibited fibrogenesis, alleviated hepatocyte apoptosis and facilitated hepatic regeneration, and a vaccine against CTGF could be developed into an effective therapeutic measure for hepatic fibrosis [53] . Based on these observations, we conducted further in vivo studies to test whether CTGF silencing by specific shRNA AAV could effectively prevent PCO. Our results showed that the specific silencing of CTGF effectively prevented and delayed the occurrence of PCO and inhibited the induction of the EMT marker a-SMA in rat LECs after surgery. Based on these results, we suggested that CTGF may represent a target for effectively preventing the occurrence of PCO.
This study found that CTGF promoted the EMT specific protein, proliferation and migration of LECs and activated the ERK signalling pathway but not the p38 and JNK signalling pathways. Additionally, our results showed that the ERK signalling pathway played an important role in CTGF-induced EMT and ECM proteins expression in HLECs. The depletion of CTGF effectively postponed the onset of PCO in a rat eye PCO model. This study provides a theoretical basis for further exploring the role of CTGF in the development of PCO, and our findings suggest that CTGF may be a new potential target for the prevention and treatment of PCO.
